Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANTA: Filgotinib Testicular Safety in IBD
NCT03201445Phase 2Terminated
- Sponsor
- Galapagos NV
- Start
- Jul 2017
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in inflammatory bowel disease (IBD) comparing Filgotinib with Placebo (2 arms). Primary endpoint: Percentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 13. Started Jul 2017; status: terminated.
02
Drugs
filgotinib
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT03201445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03201445.